HomeGLMD • NASDAQ
Galmed Pharmaceuticals Ltd
add
In the news
Financials
Income Statement
Revenue
Net Income
Revenue
Net income
| (USD) | Jun 2025info | Y/Y change |
|---|---|---|
Revenue | — | — |
Operating expense | 2.11M | 72.59% |
Net income | -2.50M | -122.97% |
Net profit margin | — | — |
Earnings per share | — | — |
EBITDA | -2.09M | -81.90% |
Effective tax rate | — | — |
Balance Sheet
Total Assets
Total Liabilities
Total assets
Total liabilities
| (USD) | Jun 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 20.53M | 108.98% |
Total assets | 22.94M | 71.98% |
Total liabilities | 2.42M | 55.79% |
Total equity | 20.52M | — |
Shares outstanding | 5.30M | — |
Price to book | 0.28 | — |
Return on assets | -25.33% | — |
Return on capital | -28.19% | — |
Cash Flow
Net Change in Cash
Net change in cash
| (USD) | Jun 2025info | Y/Y change |
|---|---|---|
Net income | -2.50M | -122.97% |
Cash from operations | -1.27M | -24.68% |
Cash from investing | -4.57M | -428.23% |
Cash from financing | 6.04M | — |
Net change in cash | 198.00K | -47.20% |
Free cash flow | -691.13K | 11.71% |
Previous close
$1.09
Day range
$0.95 - $1.08
Year range
$0.95 - $3.61
Market cap
5.32M USD
Avg Volume
4.10M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
About
Founded
2000
Website
Employees
5
